Functional complement assays are essential for diagnosing component deficiencies in inborn errors of immunity 1 and for management of patients receiving complement-inhibiting therapeutics. 2 But as gold standard haemolytic assays are labour-intensive, technically challenging, and difficult to automate, 2 increasing complement inhibitor therapeutic use 3 demands scalable alternatives. Commercially available enzyme-linked immunosorbent assays (ELISAs) and liposome-based assays offer simpler, standardised options and we compared their performance with our in-house haemolytic methods.
No takes yet. Share an insight, caveat, or question.
Hulme-Jones et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: